ArticleDiscover oncology2026
The inflammatory state of tumor peripheral liver tissue affects hepatocellular carcinoma progression and prognosis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Inflammation plays a vital role in the initiation and progression of hepatocellular carcinoma (HCC). Whether the inflammatory state of HCC peripheral liver tissue also affects tumor progression remains unclear. The medical data of HCC patients at Nanjing Drum Tower Hospital was retrospectively reviewed. Patients were divided into two groups on different inflammation grades in the peritumoral liver tissue: G 0–1 and G ≥ 2. As a preliminary exploration, RNA-seq was conducted on a limited cohort of six HCC tissues (three per group). Gene Set Enrichment Analysis (GSEA) was conducted to detect differential activation of Hallmarks pathways. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were conducted on differentially expressed genes between these two groups to elucidate enriched pathways and biological processes. Integrated machine learning algorithms and multivariate Cox regression analysis were used for prognostic gene screening and model establishment. 163 patients were included in the G 0–1 group and 207 patients in the G ≥ 2 group. More significant liver fibrosis, as well as severe coagulation and hepatic function impairment, were related to the G ≥ 2 group. Inflammatory genes, hepatic fibrosis-related genes, and Hallmarks pathways INFLAMMATORY_RESPONSE were significantly upregulated in the G ≥ 2 group. Conversely, coagulation factors, complement molecules, fibrinolysis-related molecules, hepatic metabolism-related genes, and Hallmarks pathways COAGULATION and BILE_ACID_METABOLISM were markedly upregulated in the G 0–1 group. KEGG and GO enrichment analyses yielded results consistent with above findings. The established model based on seven inflammatory-related genes performed well in prognostic prediction and risk stratification across multiple datasets. HCC patients with G ≥ 2 had an inflammatory and fibrotic phenotype with a worse prognosis, while patients with G 0–1 retained better coagulation and liver metabolic functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.